News

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

ABOUT US

News

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

Release time：

2023-10-12

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

Qilu Pharmaceutical Co., Ltd. today announced it has received approval in China from the National Medical Products Administration ("NMPA") for its Paliperidone Palmitate Suspension for Injection, 117mg/0.75ml, 156mg/1ml, 234mg/1.5ml.

The launch of Qilu’s Paliperidone Palmitate Suspension for Injection represents the first generic version of Janssen's Invega Sustenna® in China. Invega Sustenna® is a monthly long-acting atypical antipsychotic medication used to treat schizophrenia and schizoaffective disorder.

The availability of Qilu's generic Paliperidone Palmitate Suspension for Injection in China marks a significant milestone in expanding access to this vital medication and underscores Qilu's commitment to providing high-quality affordable healthcare solutions.

In addition to China, Qilu has also filed generic applications with multiple foreign regulatory agencies, including the U.S. FDA. According to IQVIA®, U.S. annual sales for Invega Sustenna® for the 12 months ended August 2023 were $2.44 billion.

none

Qilu Pharmaceutical launched the first innovative drug in China

Related News

Qilu Pharmaceutical ranks No.3 in the list of "Top 100 Enterprises in Chinese Pharmaceutical industry”

2024-09-30

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Qilu Pharmaceutical launched the first innovative drug in China

2023-09-01

Qilu Pharmaceutical Group Awarded as Socially Responsible Enterprises (Entrepreneurs) in 2022

2023-04-04

Qilu Pharmaceutical ranks No.5 in the list of "Top 100 Enterprises in Chinese Pharmaceutical Industry”